Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 28, 2025

GE HealthCare CEO Peter Arduini is forging a new chapter for the $20 billion-a-year business while drawing on Jack Welch’s legacy

View original at finance.yahoo.com
GE HealthCare CEO Peter Arduini is forging a new chapter for the $20 billion-a-year business while drawing on Jack Welch’s legacy On Jan. 4, 2023, GE HealthCare Technologies (No…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • R&D investment doubled from $750-800 million in 2018 to over $1.4 billion currently

    80% confidence

  • GE HealthCare reduced China imports from 75% to now making 85-90% of products locally for the China market

    80% confidence

  • Harmony between China and the U.S. is beneficial for the world and necessary for GE HealthCare to reach full potential

    80% confidence

  • Med tech is an American gem with 70%+ of products made in the United States and majority of IP originating there

    80% confidence

  • Authenticity and direct communication are critical for CEOs in today's world with younger employee base and social media

    80% confidence

  • GE gave employees bold assignments at a very young age and had a tough but fair culture under Jack Welch

    80% confidence

  • Innovation requires a 3 to 5 year cycle in the medical technology business

    80% confidence

  • GE HealthCare stock is up almost 50% since IPO on January 4, 2023

    80% confidence

  • As a standalone company, GE HealthCare can make decisions faster with better focus and less noise

    80% confidence

  • Larry Culp characterized himself as a down-to-earth, focused, and intentional leader

    80% confidence

  • China will eventually become the largest healthcare market with 1.4 billion people

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
GE HealthCare CEO Peter Arduini is forging a new chapter for the $20 billion-a-year business while drawing on Jack Welch’s legacy — Source | Via News | ViaNews EU